Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome

Ya-jie WANG; Xi-he CUI; Ying CHEN; Yu-jie LI; Qing YANG; Xiao-gang WENG; Yu DONG; Wei-yan CAI; Qi LI; Xiao-xin ZHU

doi:10.13422/j.cnki.syfjx.20211301

您当前的位置：

首页 >

文章列表页 >

Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome

Classic Prescriptions | 更新时间：2021-06-25

- Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 13, Pages: 1-9(2021)
- 作者机构：
  
  1.中国中医科学院中药研究所，北京 100700
  2.中国中医科学院广安门医院，北京 100053
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20211301
  CLC： R2-0;R22;R285.5;R289;R33
- Received：05 March 2021，
  
  Published Online：11 May 2021，
  
  Published：05 July 2021
- 稿件说明：
移动端阅览
王娅杰,崔羲和,陈颖等.戊己丸不同配伍方治疗肠易激综合征的比较[J].中国实验方剂学杂志,2021,27(13):1-9.

WANG Ya-jie,CUI Xi-he,CHEN Ying,et al.Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):1-9.
王娅杰,崔羲和,陈颖等.戊己丸不同配伍方治疗肠易激综合征的比较[J].中国实验方剂学杂志,2021,27(13):1-9. DOI： 10.13422/j.cnki.syfjx.20211301.

WANG Ya-jie,CUI Xi-he,CHEN Ying,et al.Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):1-9. DOI： 10.13422/j.cnki.syfjx.20211301.

摘要

目的

从神经-免疫-内分泌网络对优选的2种戊己丸配伍方干预肠易激综合征（IBS）的作用特点进行比较研究，为中医辨证论治提供一定的理论依据。

方法

采用乳鼠结肠经皮冠状动脉腔内血管成形（PTCA）球囊刺激法建立IBS慢性高敏感动物模型，分为正常组、模型组、得舒特组、戊己丸1#和2#方高、中、低剂量组，其中1#方以0.67 g·kg

-1

为中剂量，2#方以0.77 g·kg

-1

为中剂量，加倍、减半分别为高、低剂量，得舒特给药剂量为0.01 g·kg

-1

。采用腹部抬起及弓背抬高阈值评价戊己丸不同配伍方对IBS肠道敏感性的影响；采用改良后的甲苯胺蓝染色法检测对大鼠结肠组织肥大细胞（MC）密度的影响；分别采用酶联免疫吸附测定（ELISA）和免疫组化法检测大鼠血液/结肠组织中5-羟色胺（5-HT），P物质（SP），生长抑素（SS）及血管活性肠肽（VIP）的浓度/阳性表达。

结果

各组大鼠体质量随时间差异无统计学意义；与正常组比较，模型组腹部抬起和弓背抬高阈值均显著降低（

0.01），结肠组织中MC密度明显升高（

0.05），血液以及结肠组织中的5-HT，SP，SS水平均明显增加（

0.05，

0.01），结肠组织中VIP表达明显提高（

0.05）。与模型组比较，戊己丸不同配伍方均可显著提高腹部抬起和弓背抬高阈值（

0.01），明显减少结肠组织MC数量（

0.05）及5-HT，SP，SS和VIP的表达（

0.05）。分析戊己丸不同配伍方作用得出，戊己丸1#方在降低血液中5-HT，SP及SS方面不同程度地强于2#方，其中尤以对5-HT的影响的差别最为显著（

0.01）；而2#方在降低结肠5-HT阳性表达上与1#方差别无明显统计学意义，在下调SP阳性表达上显著优于1#方；对于结肠SS阳性表达，其阳性表达的强度及范围显著小于1#方（

0.05）。

结论

戊己丸不同配伍方均能调整IBS的胃肠激素紊乱，降低肠道敏感性；在整体作用上，1#方不同程度地强于2#方，而在肠道局部作用上，2#方显示出一定优势，而且1#方更长于对肠道动力学的影响，而2#方则对肠道感觉的影响更大一些。

Abstract

Objective

To compare the therapeutic efficacies of Wujiwan at two different compatibilities （No.1 and No.2） on irritable bowel syndrome （IBS） based on neuro-endocrine-immune network， and provide a theoretical basis for the treatment based on syndrome differentiation in traditional Chinese medicine （TCM）.

Method

The chronic animal model of IBS with visceral hypersensitivity was established by colon irritation via percutaneous transluminal coronary angioplasty （PTCA） in suckling rats. The animals were randomly divided into a control group， a model group， a dicetel group （0.01 g·kg

-1

）， low- （0.335 g·kg

）， medium- （0.67 g·kg

）， and high-dose （1.34 g·kg

） No. 1 Wujiwan groups， and low- （0.385 g·kg

）， medium- （0.77 g·kg

）， and high-dose （1.54 g·kg

） No. 2 Wujiwan groups. The thresholds of abdominal elevation and bow back elevation were evaluated to detect the effect of Wujiwan on intestinal sensitivity of IBS. The density of mast cells （MC） in the colonic tissue of model rats was detected by the modified toluidine blue staining method. The concentrations/positive expression of 5-hydroxytryptamine （5-HT）， substance P （SP）， somatostatin （SS）， and vasoactive intestinal peptide （VIP） in the blood/colon tissue were detected by enzyme-linked immunosorbent assay （ELISA） and immunohistochemistry （IHC） assay.

Result

There was no significant difference in body weight among different groups. Compared with the control group， the model group exhibited decreased thresholds of abdominal elevation and bow back elevation （

0.01）， increased density of MCs in the colon tissue （

0.05）， up-regulated levels of 5-HT， SP， and SS in the blood and colon tissue （

0.05，

0.01）， and elevated VIP level in the colon tissue （

0.05）. Compared with the model group， Wujiwan at different compatibilities could increase the thresholds of abdominal elevation and bow back elevation （

0.01）， diminish the count of MC in the colon tissue （

0.05）， and reduce the levels of 5-HT， SP， SS， and VIP （

0.05）. As demonstrated by the comparison of No. 1 and No. 2 Wujiwan， No. 1 was superior to No. 2 in reducing the concentrations of 5-HT， SP， and SS in the blood， especially in 5-HT （

0.01）. No significant difference between No. 1 and No. 2 in reducing 5-HT positive expression in the colon tissue was observed. Compared to the No. 1 Wujiwan， No. 2 significantly reduced SP expression， and the intensity and range of SS expression in the colon tissue in the No. 2 groups were smaller than those in the No. 1 groups （

0.05）.

Conclusion

Wujiwan at different compatibilities was capable of improving gastrointestinal hormone disorder of IBS to reduce intestinal sensitivity. In terms of systemic effect， No. 1 was superior to No. 2， while in terms of local effect， No. 2 was advantageous. No. 1 Wujiwan was superior to No. 2 in the effect on intestinal dynamics， while No. 2 had an advantageous effect on intestinal sensation over No. 1.

关键词

Keywords

references

张鸣鸣，姜敏 . 肠易激综合征发病机制研究进展［J］. 世界华人消化杂志， 2009 ， 17 （ 24 ）： 2484 - 2490 .

董星，黄适，李赟，等 . 肠易激综合征研究进展［J］. 西南国防医药， 2020 ， 30 （ 1 ）： 75 - 77 .

徐翰南，蔡征真，王云，等 . 肠道菌群对肠道神经-内分泌-免疫系统的影响及其病理生理意义［J］. 生理学报， 2020 ， 72 （ 3 ）： 347 - 360 .

陈家旭，杨维益 . 神经-内分泌-免疫网络研究概况及其与中医肝脏关系的探讨［J］. 北京中医药大学学报， 1995 ， 18 （ 4 ）： 7 - 11 .

WANG H X ， WANG Y P . Gut Microbiota-brain axis ［J］. Chin Med J （Engl）， 2016 ， 129 （ 19 ）： 2373 - 2380 .

KRAMMER L ， SOWA A S ， LORENTZ A . Mast cells in irritable bowel syndrome：a systematic review ［J］. J Gastrointestin Liver Dis ， 2019 ， 28 （ 4 ）： 463 - 472 .

BASHASHATI M ， MOOSSAVI S ， CREMON C ， et al . Colonic immune cells in irritable bowel syndrome：a systematic review and meta-analysis ［J］. Neurogastroenterol Motil ， 2018 ， doi： 10.1111/nmo.13192 http://dx.doi.org/10.1111/nmo.13192 .

YU D ， ZHU J ， ZHU M ， et al . Inhibition of mast cell degranulation relieves visceral hypersensitivity induced by pancreatic carcinoma in mice ［J］. J Mol Neurosci ， 2019 ， 69 （ 2 ）： 235 - 245 .

DOTHEL G ， BARBARO M R ， BOUDIN H ， et al . Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome ［J］. Gastroenterology ， 2015 ， 148 （ 5 ）： 1002 - 1011 .

ROLLAND-FOURCADE C ， DENADAI-SOUZA A ， CIRILLO C ， et al . Epithelial expression and function of trypsin-3 in irritable bowel syndrome ［J］. Gut ， 2017 ， 66 （ 10 ）： 1767 - 1778 .

董孝国 . P物质研究进展［J］. 商丘师范学院学报， 2012 ， 28 （ 6 ）： 86 - 89 .

李林，茹立强 . P物质、血管活性肠肽和乙酰胆碱能神经在大鼠肠道内的分布及其关系［J］. 神经解剖学杂志， 2009 ， 25 （ 6 ）： 663 - 666 .

李锋 . 5-羟色胺在功能性胃肠病内脏高敏感中的作用［J］. 现代中西医结合杂志， 2010 ， 19 （ 25 ）： 3267 - 3269 .

张建锋，刘文，侯晓杰，等 . 戊己丸的现代研究进展［J］. 中医学报， 2017 ， 32 （ 1 ）： 96 - 98 .

AL-CHEAR E D ， KAWASAKI M ， PASRICHA P J . A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development ［J］. Gastroenterology ， 2000 ， 119 （ 5 ）： 1276 - 1285

ZHU S ， MIN L ， GUO Q ， et al . Transcriptome and methylome profiling in a rat model of irritable bowel syndrome induced by stress ［J］. Int J Mol Med ， 2018 ， 42 （ 5 ）： 2641 - 2649 .

ENCK P ， AZIZ Q ， BARBARA G ， et al . Irritable bowel syndrome ［J］. Nat Rev Dis Primers ， 2016 ， doi： 10.1007/BF01395503 http://dx.doi.org/10.1007/BF01395503 .

LEE K N ， LEE O Y . The role of mast cells in irritable bowel syndrome ［J］. Gastroenterol Res Pract ， 2016 ， doi： 10.1155/2016/2031480 http://dx.doi.org/10.1155/2016/2031480 .

YU Y C ， LI J ， ZHANG M ， et al . Resveratrol improves brain-gut axis by regulation of 5-HT-dependent signaling in the rat model of irritable bowel syndrome ［J］. Front Cell Neurosci ， 2019 ， 13 ： 30 .

SOHN W ， LEE O Y ， LEE S P ， et al . Mast cell number，substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea ［J］. Scand J Gastroenterol ， 2014 ， 49 （ 1 ）： 43 - 51 .

GONKOWSKI S ， RYTEL L . Somatostatin as an active substance in the mammalian enteric nervous system ［J］. Int J Mol Sci ， 2019 ， 20 （ 18 ）： 4461 .

王娅杰，董宇，朱晓新 . 戊己丸提取物不同配伍方对豚鼠离体结肠运动影响的实验研究［J］. 中国中药杂志， 2007 ， 32 （ 20 ）： 2161 - 2165 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Difference Analysis of Pharmacokinetic Behavior of Active Ingredients in Wujiwan Between Normal Rats and Rats with Irritable Bowel Syndrome

"Compatibility" Relationship of Active Components and Heat-clearing and Blood-cooling Effect of Rehmannia glutinosa Roots

Effects of Compatibility of Ephedrae Herba，Asari Radix et Rhizoma， and Aconiti Lateralis Radix Praeparata on ILC2s-Related Factors in Lung of Allergic Rhinitis Model Mice

Compatibility Mechanism of Shangerhuang Wan in Enhancing Intestinal Motility in Rat Model of Functional Constipation by Regulating Bile Acid Metabolism

Related Author

Hong ZHANG

Ying CHEN

Zi-peng GONG

Yu DONG

Zi-yu YANG

Qing YANG

Yu-jie LI

Wei-yan CAI

Related Institution

Anhui University of Chinese Medicine

Provincial Key Laboratory of Pharmaceutics in Guizhou Province， State Key Laboratory of Functions and Applications of Medicinal Plants，Engineering Research Center for Development and Application of Ethnic Medicine and Traditional Chinese Medicine，Ministry of Education，School of Pharmaceutical Sciences，Guizhou Medical University

Henan Provincial Engineering Technology Research Center for Quality Control and Evaluation of Traditional Chinese Medicine， Henan University of Chinese Medicine

College of Agronomy， Henan Agricultural University

Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰